Type 2 Diabetes Market Size to Worth Around US$ 61.6 Bn by 2030

According to Precedence Research, the global type 2 diabetes market was estimated at US$ 29.81 billion in 2021 and is projected to worth around US$ 61.6 billion by 2030, growing at a CAGR of 8.4% from 2022 to 2030.


London, April 28, 2022 (GLOBE NEWSWIRE) -- Market competitors are launching not only novel pharmaceuticals and therapies, but also equipment and tools that can be used in the treatment and diagnosis of type 2 diabetes. As a result, the worldwide type 2 diabetes market is rising due to increased research and development activities. Market participants, as well as the government, are substantially investing in R&D activities. As a result, this aspect is contributing to the worldwide type 2 diabetes markets growth and expansion. Furthermore, type 2 diabetes is more common in children and teenagers. Obesity in children is on the rise, as are rates of type 2 diabetes in youngsters. As a result, the worldwide type 2 diabetes market is expanding due to the rising number of type 2 diabetes patients.

Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1663

Regional Snapshot

North America is the largest segment for type 2 diabetes market in terms of region. The U.S. is dominating the type 2 diabetes market in the North America region. The rising prevalence of diabetes is driving the expansion of the type 2 diabetes market in the area. The growth of the North American type 2 diabetes market is being fueled by factors such as the expansion of the healthcare sector and favorable government regulations. Furthermore, an increasing number of government initiatives and advantageous reimbursement policies are helping the region's type 2 diabetes market growth.

Europe region is the fastest growing region in the type 2 diabetes market.The UK and Germany hold the highest market share in the Europe type 2 diabetes market. The rising number of type 2 diabetic patients is propelling the type 2 diabetes market in Europe to new heights. The demand for type 2 diabetes medications is being fueled by factors such as increased research and development activities and an increase in the prevalence of obesity. Furthermore, better supply chain management is opening up attractive market expansion potential.

Scope of the Report

Report CoverageDetails
Market Size in 2021USD 29.81 Billion
CAGR8.4% From 2022 to 2030
Largest MarketNorth America
Fastest Growing RegionAsia Pacific
Base Year2021
Forecast Data2022 to 2030
Companies CoveredAmgen Inc., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Daiichi Sankyo Co. Ltd, Eli Lilly and Co., Merck & Co. Inc, Novartis AG, Novo Nordisk AS, Sanofi SA, Takeda Pharmaceutical Co. Ltd

Report Highlights

  • On the basis of drug class, insulin segment holds the largest market share in the global type 2 diabetes market. Insulin is a widely prescribed medication for the treatment of type 2 diabetes. Insulin improves the body’s metabolism while also attempting to stimulate the immune system. Insulin also aids in the regulation of blood sugar levels in the body.

  • On the basis of application, retail pharmacies segment holds the largest market share in the global type 2 diabetes market. Retail pharmacies have a vast selection of pharmaceuticals and medications. Drugs sold in retail pharmacies are inexpensive and accessible to the general public.

Ask here for more customization study@ https://www.precedenceresearch.com/customization/1663

Market Dynamics

Drivers

Surge in demand for insulin

The type 2 diabetes market growth prospects exist in the insulin segment of the market. The type 2 diabetes affects a large number of people. It’s one of the main reasons why insulin medicines are in such high demand. The insulin segment offers tremendous development and growth opportunities due to product variety and innovation. Thus, surge in demand for insulin are driving the growth of global type 2 diabetes market over the projected period.

Restraints

Lack of healthcare infrastructure in various nations

In some diabetic instances, the healthcare infrastructure is inadequate. It is a major hurdle for the type 2 diabetes market. Drug development, research, and other general market conditions are all hampered by weak healthcare infrastructure. In some regions, a lack of health infrastructure can make type 2 diabetes market expansion impossible. Furthermore, in certain areas, there may be less demand. As a result, lack of healthcare infrastructure in various nations is restricting the type 2 diabetes market growth.

Opportunities

Growing investments in research and development

The introduction of generic insulin and the rapidly expanding demand for innovative insulin in the regulation of blood sugar levels in type 2 diabetes are expected to drive the growth of global type 2 diabetes market. Lispro, a generalform of rapid acting Humalog insulin was launched in March 2019 by Eli Lilly and Company. It will be available in the U.S. for low price as compared to Humalog, making it more affordable for type 2 diabetes patients. Thus, growing investments in research and development is providing growth prospects for the global type 2 diabetes market.

Challenges

Stringent government regulations

The market challenges are imposed by rigorous government regulations. Diabetes medications are available in a broad variety around the world. Regulatory requirements also cause delays in the approval of new medications. The medicine approval regulator’s standards are stringent, influencing the type 2 diabetes market’s supply and output. As a result, stringent government regulations are major challenges for the growth of global type 2 diabetes market over the projected period.

Browse more related reports@ https://www.precedenceresearch.com/industry/healthcare

Recent Developments

  • Rybelsus oral tablets for adult patients with type 2 diabetes were approved by the U.S. FDA in September 2019. Rybelsus is the first non-injectable glucagon like peptide receptor protein therapy licensed in the U.S.

Market Segmentation

By Drug Class

  • Dipeptidyl Peptidase-4
  • Inhibitors
  • Glucagon-Like Peptide
  • Receptor Agonists
  • Thiazolidinediones
  • Alpha-Glucosidase Inhibitors
  • Sulfonylureas
  • Secretagogues
  • Biguanides
  • Sodium Glucose Cotransport 2 Inhibitors

By Application

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Click Here to View Full Report Table of Contents

Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1663

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us:

https://www.linkedin.com/company/precedence-research/

https://www.facebook.com/precedenceresearch/

https://twitter.com/Precedence_R